Assignee
BRIGHT PEAK THERAPEUTICS AG
CH·4 granted patents·18 pending applications·3 citations·filing 2021–2024
Top patents by PatentIndex Score
22 records- 0180US12173062B2Modified TNF-α antibodies and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Granted Dec 24, 2024·2 cites·18 claims
- 0274US11633488B2Modified IL-2 polypeptides and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2021·Granted Apr 25, 2023·1 cites·20 claims
- 0364US12521441B2Modified IL-2 polypeptides and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Granted Jan 13, 2026·0 cites·11 claims
- 0458US12383631B2Immune antigen specific IL-18 immunocytokines and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Granted Aug 12, 2025·0 cites·20 claims
- 0556US2025186594A1Il-18 polypeptides modified with polymersBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0654US2024158537A1Synthetic il-7 and il-7 immunocytokinesBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0754US2025188166A1Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0854US2025186597A1Targeted immune activation with il-18 immunocytokinesBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0954US2023250181A1Modified checkpoint inhibitors and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1053US2025197467A1Activatable il-18 immunocytokines and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1153US2024132563A1Bifunctional cytokine compositionsBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1252US2025213705A1Psma targeting ligands and methods of useBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1352US2024424127A1Il-7 polypeptides, immunocytokines comprising same, and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1451US2024376170A1Conditionally activated proteins and methods of useBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1550US2023201365A1Modified cd20 antibodies and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1650US2024417436A1Conditionally activated immunocytokines and methods of useBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1749US2024400614A1Cleavable peptides and methods of use thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1848US2024116997A1Activatable il-18 polypeptidesBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1948US2023181754A1Modified checkpoint inhibitors and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2048US2023357342A1Modified il-18 polypeptidesBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2146US2023201364A1Antibody conjugates and manufacture thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2245US2022056091A1Modified il-18 polypeptides and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BRIGHT PEAK THERAPEUTICS AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →